Print

AllaChem Announces the Completion of Pre-Clinical Studies With ONC1-13B, a New Effective Anti-Androgen for the Treatment of Prostate and Breast Cancers  
8/5/2013 8:52:31 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Hallandale Beach, Fl – July 28, 2013 - Alla Chem, LLC announced today the completion of pre-clinical studies with ONC1-13B, a next in-class small molecule androgen receptor inhibitor for the treatment of prostate and breast cancers. The results will be reported at the 3rd World Congress on Cancer Science & Therapy, October 21-23, 2013, in San Francisco . The submission package for the phase I/II clinical studies is under review by the Russian Regulatory Agencies.

The phase I / II clinical studies will be conducted in 12-24 volunteers with progressive metastatic castration-resistant prostate cancer in 4-6 clinical sites in the Russian Federation . The studies will evaluate ONC1-13B efficacy, safety, tolerability and pharmacokinetics upon single and repeated oral administration of 40, 80, 160, and 320 mg doses.

CONTACT:

Alena Ivachtchenko, MBA

Director Business Development

Phone: 1-858-35-6627

E-mail: alena.ivachtchenko@allachem.com; av@allachem.com

www.allachem.com

Help employers find you! Check out all the jobs and post your resume.

//-->